Fujifilm and Dr Reddy’s have decided to terminate the Memorandum of Understanding (MoU) signed on 28 July 2011, which would have seen Fujifilm owning 51% of a joint venture targeting Japans growing generics market – the sixth largest generics market in the world.

Fujifilm, however, has now decided to focus on proprietary cancer drugs, super generics and biologicals. Fujifilm launched a biosimilars joint venture with biotech firm Kyowa Hakko Kirin on 27 March 2012, initially focusing on the development of biosimilar adalimumab [1].

Fujifilm will continue to collaborate with Dr Reddy’s in other fields, such as active pharmaceutical ingredients (APIs), development and manufacturing, contract research, development and manufacturing; and the development and marketing of super generics.

Despite this setback Dr Reddy’s stated that the generics giant is still committed to a planned entry into Japan to bring affordable and innovative drugs to more patients worldwide.

Related article

Japanese government promoting generics

Reference

1.  GaBI Online - Generics and Biosimilars Initiative. Fujifilm and Kyowa launch biosimilars joint venture [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Jun 7]. Available from: www.gabionline.net/Biosimilars/News/Fujifilm-and-Kyowa-launch-biosimilars-joint-venture

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.